JMD Position Available: Editor-In-Chief
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
A more recent version of this article appeared on May 1, 2008

Published online before print April 10, 2008
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
jmoldx.2008.070167v1
10/3/236    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szankasi, P.
Right arrow Articles by Bahler, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szankasi, P.
Right arrow Articles by Bahler, D. W.
Copyright © 2008 American Society for Investigative Pathology
Journal of Molecular Diagnostics, doi:10.2353/jmoldx.2008.070167

Accepted for publication January 15, 2008.

Article

A New DNA-Based Test for Detection of Nucleophosmin Exon 12 Mutations by Capillary Electrophoresis

Philippe Szankasi*@, Mohamed Jama*, and David W. Bahler{dagger}

From the Associated Regional and University Pathologists (ARUP) Institute for Clinical and Experimental Pathology,* and the Department of Pathology,{dagger} University of Utah, Salt Lake City, Utah

@ To whom correspondence should be addressed. E-mail: szankasi{at}aruplab.com.


  Abstract

Mutations in nucleophosmin (NPM1) exon 12 are thought to be the most common genetic event in acute myelogenous leukemia (AML) and to confer favorable clinical prognoses. In this report, we describe a simple molecular test for the detection of NPM1 exon 12 mutations in patients with AML using polymerase chain reaction amplification of genomic DNA followed by the analysis of amplification products by capillary electrophoresis. Mutations were reproducibly detected when present in at least 5% of cells, and all NPM1 exon 12 mutations reported to date in AML could be identified using this method. This method was successfully employed using paraffin-extracted DNA, allowing for the examination of archived clinical specimens, and the assay was validated by the direct sequencing of 33 patient samples. This sensitive test is straightforward to perform and provides important information that can influence both the clinical management and treatment options for many patients with AML.




This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
G. Wertheim and A. Bagg
Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies
J. Mol. Diagn., May 1, 2008; 10(3): 198 - 202.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Society for Investigative Pathology and the Association for Molecular Pathology.